Spaulding Clinical Announces New Strategic Partnership With Frontage Laboratories, Inc.
WEST BEND, Wis., Sept. 12, 2011 /PRNewswire/ -- Frontage Laboratories, Inc., a global full-service Clinical Research Organization with facilities in the US and China, and Spaulding Clinical Research, LLC, a US-based, leading-edge Clinical Pharmacology Unit, ECG Core Lab, and Medical Device Manufacturer have entered into a strategic partnership agreement. This synergistic and cost-effective partnership establishes a global footprint by combining Frontage's presence in China and its expertise in drug formulation and Bioanalytical analysis, along with Spaulding Clinical's Cardiac Safety and fully-automated Clinical Pharmacology facility.
As part of the relationship, Spaulding Clinical will perform all intense electrocardiographic studies in its facility and provide ECG Core Lab services on behalf of Frontage. In return, Frontage will provide bioanalytical method development and sample processing, formulation development and clinical trial product supplies for Spaulding Clinical, as well as serve as one of the clinical sites for Spaulding Clinical clients in China.
"Throughout the due diligence process, we were thoroughly impressed with the innovative, quality-focused clinical conduct we witnessed at Spaulding," states Song Li, PhD, CEO and Chairman of Frontage Laboratories, Inc. "The collaboration with Spaulding Clinical will enable Frontage to better service our current and potential clients in a more comprehensive approach, especially in the areas of cardiac safety, thorough QT, and ECG Core Lab."
Randy Spaulding, CEO and Founder of Spaulding Clinical, states, "This collaboration represents another step forward in meeting our strategic objectives of providing the highest quality global clinical development facilities to our clients interested in accelerating drug development. Together, Frontage and Spaulding Clinical will deliver the first US-based fully-automated Clinical Pharmacology unit in China."